Merck bags Japanese approval for a weekly diabetes drug

Merck ($MRK), building on the success of its diabetes blockbuster Januvia, won a first global approval for a long-acting form of the drug, convincing Japanese regulators to approve its new weekly product. Called omarigliptin, Merck's treatment works by blocking a protein called DPP-4 to lower blood glucose levels. In Phase III trials, the new drug measured up to Januvia, a daily DPP-4 treatment that brought in about $3.9 billion for Merck last year. The company expects to launch omarigliptin in Japan under the trade name Marizev. Merck has said it's on track to submit the drug in the U.S. by the end of this year. Release

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.